title: Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation.
abstract: Angiotensin I-converting enzyme inhibitors (ACEi) cause both chronic and acute side effects, including rare but potentially life-threatening angioedema (AE). The main hypothesis to be tested in this study was that metallopeptidases and kinin receptors are present in oropharyngeal tissues and that their expression is modulated by ACEi and inflammation. Novel real-time polymerase chain reaction analysis was developed and allowed the relative quantification of tissue's gene expression for neprilysin, membrane-bound aminopeptidase P (mAPP), and both B1 and B2 kinin receptor subtypes in tongue, parotid gland, and laryngeal tissue (areas especially involved in the gravest clinical forms of AE) and in kidney in a porcine model (single injection or 7-day ACEi oral treatments applied or lipopolysaccharide injected as a positive inflammatory control). The results provide evidence of the expression and activities of kininases in oropharyngeal tissues in the swine. ACEi treatment modulated the expression of neutral endopeptidase and mAPP mRNA, but the corresponding enzyme activities and that of angiotensin I-converting enzyme (ACE) were generally stable in tissues. The 7-day ACEi treatment up-regulated both kinin receptor mRNAs in the oropharynx and the B1 receptor mRNA in the lingual vascular endothelium (immunohistochemistry). The inhibition of ACE in plasma is responsible for an accumulation of bradykinin and des-arginine9-bradykinin generated during activation of the contact system with glass beads. The expression of critical components of the kallikrein-kinin system in the oropharyngeal tissues supports the role of kinins in ACEi-induced AE.
authors.affiliation: Université de Montréal, Faculté de Pharmacie, Room 3190, 2900 Blvd.Edouard-Montpetit, C.P. 6128, succ Centre-ville, Montréal, Québec H3C 3J7, Canada.
authors.forename: Marie Eve
authors.initials: ME
authors.lastname: Moreau
authors.forename: Pascal
authors.initials: P
authors.lastname: Dubreuil
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Molinaro
authors.forename: Miguel
authors.initials: M
authors.lastname: Chagnon
authors.forename: Werner
authors.initials: W
authors.lastname: Müller-Esterl
authors.forename: Yves
authors.initials: Y
authors.lastname: Lepage
authors.forename: François
authors.initials: F
authors.lastname: Marceau
authors.forename: Albert
authors.initials: A
authors.lastname: Adam
mesh_terms: D000626:Aminopeptidases / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D002097:C-Reactive Protein / Q000032:analysis; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D007249:Inflammation; D008297:Male; D045726:Metalloproteases / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D015260:Neprilysin / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D009960:Oropharynx / Q000201:enzymology / Q000378:metabolism*; D007703:Peptidyl-Dipeptidase A / Q000032:analysis / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D011897:Random Allocation; D018002:Receptors, Bradykinin / Q000032:analysis / Q000187:drug effects / Q000378:metabolism*; D034421:Sus scrofa; D015854:Up-Regulation
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D012333:RNA, Messenger; D018002:Receptors, Bradykinin; D002097:C-Reactive Protein; D045726:Metalloproteases; D000626:Aminopeptidases; C022750:X-Pro aminopeptidase; D007703:Peptidyl-Dipeptidase A; D015260:Neprilysin